1.I am a (Choose all that apply)

Patient

Care Partner of a Patient

Health Care Provider

Industry Partner

Other (please specify)

2.Which of the following best applies to you?

This is my first IMF Educational Program

I attend IMF Educational Programs on a regular basis

I have attended IMF Educational Programs previously, but not in the last year

3.How long ago were you or the person you care for diagnosed? (choose one)

Less than 3 months

Between 3 months and 1 year

Between 1 and 5 years

Between 5 and 10 years

15 or more years

Not applicable

Please only evaluate the presentations that you attended.

4.Please rate the value of each presentation.

1 - Not Valuable

2 - Slightly Valuable

3 - Moderately Valuable

4 - Very Valuable

5 - Extremely Valuable

Hot Topics in Myeloma - Joseph Mikhael, MD

1 - Not Valuable

2 - Slightly Valuable

3 - Moderately Valuable

4 - Very Valuable

5 - Extremely Valuable

Myeloma 101: The Big Picture Perspective with Q & A - Joseph Mikhael, MD

1 - Not Valuable

2 - Slightly Valuable

3 - Moderately Valuable

4 - Very Valuable

5 - Extremely Valuable

The Unseen Impact of Myeloma: Taking Care of your Emotional Health - Katie Atkins, LCSW

1 - Not Valuable

2 - Slightly Valuable

3 - Moderately Valuable

4 - Very Valuable

5 - Extremely Valuable

Navigating Insurance & Medical Bills - Laura Beilke, ESQ

1 - Not Valuable

2 - Slightly Valuable

3 - Moderately Valuable

4 - Very Valuable

5 - Extremely Valuable

Advocacy Update - Danielle Doheny

1 - Not Valuable

2 - Slightly Valuable

3 - Moderately Valuable

4 - Very Valuable

5 - Extremely Valuable

Myeloma 202: Immunotherapy Made Simple - Joseph Mikhael, MD

1 - Not Valuable

2 - Slightly Valuable

3 - Moderately Valuable

4 - Very Valuable

5 - Extremely Valuable

Understanding Clinical Trials - Joseph Mikhael, MD & Robin Tuohy

1 - Not Valuable

2 - Slightly Valuable

3 - Moderately Valuable

4 - Very Valuable

5 - Extremely Valuable

Q & A with Guest Panel

1 - Not Valuable

2 - Slightly Valuable

3 - Moderately Valuable

4 - Very Valuable

5 - Extremely Valuable

5.This presentation increased my understanding of the topic.

1 - Strongly Disagree

2 - Disagree

3 - Neutral

4 - Agree

5 - Strongly Agree

Hot Topics in Myeloma - Joseph Mikhael, MD

1 - Strongly Disagree

2 - Disagree

3 - Neutral

4 - Agree

5 - Strongly Agree

Myeloma 101: The Big Picture Perspective with Q & A - Joseph Mikhael, MD

1 - Strongly Disagree

2 - Disagree

3 - Neutral

4 - Agree

5 - Strongly Agree

The Unseen Impact of Myeloma: Taking Care of your Emotional Health - Katie Atkins, LCSW

1 - Strongly Disagree

2 - Disagree

3 - Neutral

4 - Agree

5 - Strongly Agree

Navigating Insurance & Medical Bills - Laura Bielke, ESQ

1 - Strongly Disagree

2 - Disagree

3 - Neutral

4 - Agree

5 - Strongly Agree

Advocacy Update - Danielle Doheny

1 - Strongly Disagree

2 - Disagree

3 - Neutral

4 - Agree

5 - Strongly Agree

Myeloma 202: Immunotherapy Made Simple - Joseph Mikhael, MD

1 - Strongly Disagree

2 - Disagree

3 - Neutral

4 - Agree

5 - Strongly Agree

Understanding Clinical Trials - Joseph Mikhael, MD & Robin Tuohy

1 - Strongly Disagree

2 - Disagree

3 - Neutral

4 - Agree

5 - Strongly Agree

Q & A with Guest Panel

1 - Strongly Disagree

2 - Disagree

3 - Neutral

4 - Agree

5 - Strongly Agree

6.After attending this program, rate your overall perception of clinical trials.

1 - Extremely Negative

2 - Negative

3 - Neutral

4 - Positive

5 - Extremely Positive

1 - Extremely Negative

2 - Negative

3 - Neutral

4 - Positive

5 - Extremely Positive

7.After attending this program, how open would you be to considering a clinical trial if recommended by your doctor?

1 - Not at all Open

2 - Slightly Open

3 - Moderately Open

4 - Very Open

5 - Extremely Open

1 - Not at all Open

2 - Slightly Open

3 - Moderately Open

4 - Very Open

5 - Extremely Open

8.I plan to share what I learned from this program with: (select all that apply)

My healthcare team

My care partner

My family or friends

My support group

On social media

I do not plan to share

Other (please specify)

9.Please share any additional feedback